Restoring the Permanently Lost Foundation Guild™ is Possible.
Notitia's proprietary Foundation Guild™ Microbiome R&D Platform allows us to develop unique and effective treatments for various diseases and complications. Under our Foundation Guild™ Clinical Program, we currently have two leading drug candidates being tested in multiple clinical conditions. Our R&D platform allows us to launch additional conditions or drugs quickly and effectively.
Bacterial Medicine (BM306)
BM306 is an investigational live biotherapeutic product that contains the Foundation Guild™ bacteria in a defined consortium. This investigational drug is designed to treat diseases by replenishing the missing or extinct Foundation Guild™ bacteria in a patient's gut microbiome.
Clinical Pipeline
| Condition | Pre-clinical | Phase 1 |
Phase 2 |
Phase 3 |
|---|---|---|---|---|
| Functional Gastrointenstinal Disorder (FGID) in Long COVID-19 patients | Completed | Completed | in-progress | |
Links to studies |
||||
| Multiple Sclerosis (MS) | Completed | Completed | ||
Links to studies |
||||
| Parkinson's Disease | Completed | Completed | ||
| Early/End-stage Diabetic Kidney Disease (DKD) | Completed | Completed | ||
| Side-effects of Cancer Chemotherapy | Completed | Completed | ||
| Prader-Willi Syndrome (PWS) | Completed | |||
We are thrilled to announce our groundbreaking microbiome discovery regarding the Foundation Guild bacteria published in the prestigious journal Cell. Read more about our discovery here, or visit our online store to purchase the latest microbiome products designed for this “core microbiome” target. Try it today and experience the Notitia difference!
